Oasmia is a specialty pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, in several indications, including cancer.
Regulatory September 20, 2021Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB
Non Regulatory September 17, 2021Oasmia signs agreement with FarmaMondo to commercialize Paclical® in Russia & CIS
Non Regulatory August 31, 2021Oasmia to present at Aktiedagen Stockholm on September 7
Oasmia Pharmaceutical published its interim report for the second quarter of 2021 on August 19, 2021, at 08.00 am CEST.
The company will hold a conference call and an online presentation on the same day at 10.00 am CEST. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.